INNOGEN-B (02591) Issues First Prescription for Core Type 2 Diabetes Treatment Product in Macau at HuaBao Medical Center

Stock News

09/12

INNOGEN-B (02591) announced that the company has been actively advancing the global expansion of its core product (isupaglutide alpha) and received BLA (Biologics License Application) approval for its core product to treat type 2 diabetes (T2D) in the Macao Special Administrative Region of the People's Republic of China (Macau) in June 2025. The company's board of directors is pleased to announce that on September 12, 2025, the first prescription for the company's core product for treating type 2 diabetes in Macau was issued at Macau HuaBao Medical Center, marking the official entry of the core product into the commercial sales stage in Macau.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1139178921"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1139178921\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1139178921?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-12 21:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139178921","market":"sg","top_or_hot":-1,"title":"INNOGEN-B (02591) Issues First Prescription for Core Type 2 Diabetes Treatment Product in Macau at HuaBao Medical Center","media":"Stock News","content":"<p>INNOGEN-B (02591) announced that the company has been actively advancing the global expansion of its core product (isupaglutide alpha) and received BLA (Biologics License Application) approval for its core product to treat type 2 diabetes (T2D) in the Macao Special Administrative Region of the People's Republic of China (Macau) in June 2025. The company's board of directors is pleased to announce that on September 12, 2025, the first prescription for the company's core product for treating type 2 diabetes in Macau was issued at Macau HuaBao Medical Center, marking the official entry of the core product into the commercial sales stage in Macau.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INNOGEN-B (02591) Issues First Prescription for Core Type 2 Diabetes Treatment Product in Macau at HuaBao Medical Center</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINNOGEN-B (02591) Issues First Prescription for Core Type 2 Diabetes Treatment Product in Macau at HuaBao Medical Center\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-09-12 21:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>INNOGEN-B (02591) announced that the company has been actively advancing the global expansion of its core product (isupaglutide alpha) and received BLA (Biologics License Application) approval for its core product to treat type 2 diabetes (T2D) in the Macao Special Administrative Region of the People's Republic of China (Macau) in June 2025. The company's board of directors is pleased to announce that on September 12, 2025, the first prescription for the company's core product for treating type 2 diabetes in Macau was issued at Macau HuaBao Medical Center, marking the official entry of the core product into the commercial sales stage in Macau.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02591","symbol_name":"銀諾醫藥－Ｂ","start_time":0,"source_url":"","article_id":"1139178921","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139178921","pubTimestamp":1757682617,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"INNOGEN-B (02591) announced that the company has been actively advancing the global expansion of its core product (isupaglutide alpha) and received BLA (Biologics License Application) approval for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159891":"医疗","02591":"银诺医药－Ｂ","BK1161":"生物科技"},"translate_title":"英诺健-B(02591)在华宝医疗中心开出澳门核心2型糖尿病治疗产品首张处方","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159891":1,"02591":1},"content_text":"INNOGEN-B (02591) announced that the company has been actively advancing the global expansion of its core product (isupaglutide alpha) and received BLA (Biologics License Application) approval for its core product to treat type 2 diabetes (T2D) in the Macao Special Administrative Region of the People's Republic of China (Macau) in June 2025. The company's board of directors is pleased to announce that on September 12, 2025, the first prescription for the company's core product for treating type 2 diabetes in Macau was issued at Macau HuaBao Medical Center, marking the official entry of the core product into the commercial sales stage in Macau.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}